Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.

about

Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.

Item

http://www.wikidata.org/entity/Q37613039

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Evaluation of Doravirine Pharm ...... oravirine in Healthy Subjects.

@en

Evaluation of Doravirine Pharm ...... oravirine in Healthy Subjects.

@nl

type

Item

label

Evaluation of Doravirine Pharm ...... oravirine in Healthy Subjects.

@en

Evaluation of Doravirine Pharm ...... oravirine in Healthy Subjects.

@nl

prefLabel

Evaluation of Doravirine Pharm ...... oravirine in Healthy Subjects.

@en

Evaluation of Doravirine Pharm ...... oravirine in Healthy Subjects.

@nl

P1476

Evaluation of Doravirine Pharm ...... oravirine in Healthy Subjects.

@en

P2093

Ilias Triantafyllou

http://www.w3.org/2001/XMLSchema#string

Ka Lai Yee

http://www.w3.org/2001/XMLSchema#string

Li Fan

http://www.w3.org/2001/XMLSchema#string

Marian Iwamoto

http://www.w3.org/2001/XMLSchema#string

Mike Di Spirito

http://www.w3.org/2001/XMLSchema#string

Ming-Tain Lai

http://www.w3.org/2001/XMLSchema#string

Patrice Auger

http://www.w3.org/2001/XMLSchema#string

Rachael Liu

http://www.w3.org/2001/XMLSchema#string

Rosa I Sanchez

http://www.w3.org/2001/XMLSchema#string

Sauzanne G Khalilieh

http://www.w3.org/2001/XMLSchema#string

P2860

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability

Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.

In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Characterizing Class-Specific Exposure-Viral Load Suppression Response of HIV Antiretrovirals Using A Model-Based Meta-Analysis.

A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.

Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients.

In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.

P31

scholarly article

P356

10.1128/AAC.01757-16

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27872069

http://www.w3.org/2001/XMLSchema#string

P932

5278744

http://www.w3.org/2001/XMLSchema#string